A 62-year-old woman with squamous cell carcinoma of the lung presents with hypercalcemia (Ca2+ 12.5 mg/dL), elevated PTHrP levels, and polyuria. She is mildly symptomatic with nausea and confusion. After aggressive IV hydration, what is the drug of choice for persistent hypercalcemia in this paraneoplastic setting?

Explanation

## PTHrP-Mediated Hypercalcemia in Malignancy **Key Point:** Bisphosphonates are the gold-standard second-line agent for paraneoplastic hypercalcemia after hydration fails. They inhibit osteoclast-mediated bone resorption, the primary mechanism in PTHrP-secreting tumors. ### Pathophysiology of Paraneoplastic Hypercalcemia ```mermaid flowchart TD A[Squamous cell lung cancer]:::outcome --> B[Ectopic PTHrP secretion]:::outcome B --> C[Increased osteoclast activity]:::outcome C --> D[Bone resorption]:::outcome D --> E[Serum calcium ↑]:::outcome E --> F{Symptomatic?}:::decision F -->|Mild| G[Hydration + Bisphosphonate]:::action F -->|Severe| H[Hydration + Bisphosphonate + Calcitonin]:::action ``` **High-Yield:** PTHrP (parathyroid hormone-related peptide) is secreted by 80% of hypercalcemic malignancies, especially squamous cell carcinomas of lung, kidney, and breast. It mimics PTH but is not suppressed by high calcium. ### Management Algorithm After Hydration | Step | Agent | Mechanism | Onset | Duration | |------|-------|-----------|-------|----------| | **1st line** | IV hydration (0.9% saline) | Dilution, renal clearance | Immediate | 24–48 hrs | | **2nd line** | **Bisphosphonates** (zoledronic acid 4 mg IV) | Osteoclast inhibition | 3–5 days | 2–4 weeks | | **Adjunct** | Calcitonin (4 IU/kg SC/IV) | Rapid osteoclast shutdown | 2–4 hours | 24–48 hrs | | **Chronic** | Denosumab (RANKL inhibitor) | Osteoclast precursor inhibition | 3–7 days | 4–6 weeks | **Clinical Pearl:** In this case, the patient is mildly symptomatic after hydration — bisphosphonates are the appropriate next step. Calcitonin is reserved for severe symptomatic hypercalcemia (Ca2+ >13 mg/dL with altered mental status, arrhythmias) requiring immediate reduction. ### Why Bisphosphonates Are First-Line for Paraneoplastic Hypercalcemia 1. **Mechanism:** Bisphosphonates (e.g., zoledronic acid, pamidronate) bind to hydroxyapatite in bone and inhibit osteoclast-mediated resorption — the primary pathology in PTHrP-secreting tumors. 2. **Efficacy:** 60–90% response rate; reduces calcium by 2–4 mg/dL over 3–5 days. 3. **Duration:** Effect lasts 2–4 weeks, allowing time for tumor-directed therapy (chemotherapy, radiation). 4. **Safety:** Well-tolerated; main risk is osteonecrosis of the jaw (ONJ) with prolonged use. **Mnemonic:** **BIPHOSPHONATES = Bone Inhibition, Persistent effect** (vs calcitonin's brief action). ### Why Other Agents Are Inappropriate - **Calcitriol (1,25-dihydroxyvitamin D3):** Increases intestinal calcium absorption and osteoclast activity — **worsens hypercalcemia**. Used only in granulomatous diseases (sarcoidosis, TB) where macrophages produce calcitriol. - **Thiazide diuretics:** Decrease urinary calcium excretion — **contraindicated** in hypercalcemia. Loop diuretics (furosemide) are preferred during hydration. - **Vitamin D supplementation:** Increases calcium absorption — **absolutely contraindicated** in paraneoplastic hypercalcemia. **Warning:** Do not confuse PTHrP-mediated hypercalcemia (osteoclast-driven) with calcitriol-mediated hypercalcemia (intestinal absorption-driven). The former requires bisphosphonates; the latter requires corticosteroids. [cite:Harrison 21e Ch 297; Robbins 10e Ch 7]